These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19207973)

  • 1. Management and prevention of drug resistance in chronic hepatitis B.
    Zoulim F; Durantel D; Deny P
    Liver Int; 2009 Jan; 29 Suppl 1():108-15. PubMed ID: 19207973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral-resistant hepatitis B virus: can we prevent this monster from growing?
    Zoulim F; Buti M; Lok AS
    J Viral Hepat; 2007 Nov; 14 Suppl 1():29-36. PubMed ID: 17958640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathobiology of HBV mutants and clinical impact for treatment monitoring.
    Si Ahmed SN; Zoulim F
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):309-20. PubMed ID: 19344244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus resistance to nucleos(t)ide analogues.
    Zoulim F; Locarnini S
    Gastroenterology; 2009 Nov; 137(5):1593-608.e1-2. PubMed ID: 19737565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug resistance in antiviral therapy.
    Locarnini S; Bowden S
    Clin Liver Dis; 2010 Aug; 14(3):439-59. PubMed ID: 20638024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.
    Locarnini S; Warner N
    Antivir Ther; 2007; 12 Suppl 3():H15-23. PubMed ID: 18284179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral therapy of chronic hepatitis B: prevention of drug resistance.
    Fournier C; Zoulim F
    Clin Liver Dis; 2007 Nov; 11(4):869-92, ix. PubMed ID: 17981233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of chronic hepatitis B and the implications of viral resistance to therapy.
    Mauss S; Wedemeyer H
    Expert Rev Anti Infect Ther; 2008 Apr; 6(2):191-9. PubMed ID: 18380601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug resistance after lamivudine therapy for chronic hepatitis B.
    Sarrecchia C; Volpi A; Sordillo P; Andreoni M
    Int J Infect Dis; 2009 May; 13(3):e133-4. PubMed ID: 18990599
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiviral therapy of chronic hepatitis B.
    Zoulim F
    Antiviral Res; 2006 Sep; 71(2-3):206-15. PubMed ID: 16716414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
    Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
    J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Future perspectives and strategies in managing resistance to analogue antiviral drugs in the treatment of chronic hepatitis B].
    Bourlière M
    Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S34-6. PubMed ID: 17075495
    [No Abstract]   [Full Text] [Related]  

  • 13. Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance.
    Zoulim F; Locarnini S
    Liver Int; 2013 Feb; 33 Suppl 1():116-24. PubMed ID: 23286855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro models for studying hepatitis B virus drug resistance.
    Zoulim F
    Semin Liver Dis; 2006 May; 26(2):171-80. PubMed ID: 16673295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studies.
    Tenney DJ
    Antivir Ther; 2010; 15(3 Pt B):529-35. PubMed ID: 20516575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of treatment failure in chronic hepatitis B.
    Zoulim F; Locarnini S
    J Hepatol; 2012; 56 Suppl 1():S112-22. PubMed ID: 22300461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing landscape of antiviral resistance management in chronic hepatitis B.
    Nguyen T; Locarnini S; Desmond P
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1314-7. PubMed ID: 18853991
    [No Abstract]   [Full Text] [Related]  

  • 18. [Definitions of resistance to analogue antiviral drugs in the treatment of chronic hepatitis B].
    Zoulim F
    Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S9-11. PubMed ID: 17075488
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of hepatitis B: new perspectives].
    Trépo C; Zoulim F
    Gastroenterol Clin Biol; 2009; 33(8-9):811-7. PubMed ID: 19560888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits and risks of nucleoside analog therapy for hepatitis B.
    Dienstag JL
    Hepatology; 2009 May; 49(5 Suppl):S112-21. PubMed ID: 19399795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.